If you are an early stage medtech innovator and want to talk about your device’s or product’s path to regulatory approval, including preclinical studies, or if you just want to talk about what we are seeing in medtech innovation in the southeast and beyond, we want to connect with you at SEMDA 2016.
SEMDA is hosting the 2016 edition of its annual flagship conference at the Music City Center in Nashville May 17-19. For the first time the organization we have happily supported for many years is taking action on its goal of increasing its regional reach by hosting SEMDA 2016 outside of its Atlanta headquarters.
While Atlanta is home for us as well, we couldn’t be happier to make the four hour road trip to SEMDA 2016 in Music City. Here’s what we are particularly looking forward to.
The networking and breadth of the attendees
SEMDA always attracts a great mix of medtech entrepreneurs, medium and large device companies, investors and affiliated service providers. Based on the attendee list, 2016 is no different. The opportunity to expand our network and gain insights and perspectives from innovators and industry leaders across the entire medtech and medical device spectrum will be significant.
The next batch of startups
Year after year, young medtech companies at SEMDA come to the fore; generate funding and advance to the next step on the path to preclinical and beyond. Companies like NFant Labs, SweetBio, InvisionHeart and OBMedical are SEMDA conference alumni.
From smaller medical device companies like Surefire Medical who desperately need to minimize the “thousand-dollar-days” and investment “burn” to the massively successful ventures like CardioMEMS (now officially part of Abbott via St. Jude Medical) we provide industry leading preclinical testing and training. We can help you get to your goal, be it a financial exit or inflection point, regulatory or executive approval or a successful medical device training program for practicing surgeons. GLP in 8 days? Yes, that’s possible, too.
In our sponsors’ own words:
Our experience with T3 Labs for the CardioMEMS device created new knowledge and refinements to the device that resulted in a product that was highly mature at the time we started our clinical trials in humans.” – Jason White, Senior Director of Product Development, St. Jude Medical
“T3’s recommendation for the model shift based on their experience and expertise was much more practical for this application based on our device’s capabilities and needs. I am convinced this recommendation has accelerated our product refinement testing and preclinical trials saving ALung time and money at every step along the way.” – Jeremy Kimmel, PhD, Director New Technology, ALung Technologies
Which among the startup and early stage companies will reveal themselves among the next generation of first-in-type or first-in-man solutions at SEMDA 2016? We can’t wait to see for ourselves!
Contributing to the program and learning opportunities
T3 Testing Program Director Deepal Panchal
Conferences are a key component of our marketing program. When integrated into a broader content marketing strategy, conferences help improve lead generation for the next set of medtech companies selecting T3 as their lab of choice for preclinical testing and training. Preclinical Program Director Deepal Panchal participates actively in T3’s marketing program. We are looking forward to having her along side T3 Board Member Tif Wilson share how scientists’ support of marketing can be done with great efficiency and effect in a session entitled “How Online Presence & Content Marketing Affect Your E-Valuation,” on Wednesday, May 18 at 2:45 p.m.
Let’s connect at SEMDA 2016!
Contact:
Andrew Stevenson, Executive Director, andrew.stevenson@emoryhealthcare.org or
Deepal Panchal, Testing Program Director, deepal.panchal@emoryhealthcare.org